AACC Webinar: Kidney Biomarkers and Shrunken Pore Syndrome*

29. Aug 2019 | 5 min read

AACC Webinar: Kidney Biomarkers and Shrunken Pore Syndrome*


The Use of Biomarkers in Chronic Kidney Disease and the Novel Disorder Shrunken Pore Syndrome (SPS)*


*this webinar is supported by Gentian

This AACC webinar* with Anders Grubb (MD, PhD, Professor in Clinical Chemistry, Lund University) focuses on renal biomarkers. Dr. Grubb will discuss the pros and cons of cystatin C and creatinine as kidney markers, and also share his insight about the novel disorder Shrunken Pore Syndrome (SPS):

  • How SPS is diagnosed
  • The mortality of SPS
  • The most common death causes associated with SPS
  • Hypotheses concerning its pathophysiology and treatment"


Kidney disorders

Kidney disorders are very common and represent a significant and growing clinical problem. Such disorders are usually diagnosed by identifying a decrease in estimated Glomerular Filtration Rate (eGFR) using a creatinine- or cystatin C-based estimating equation for GFR. Dr. Grubb will show how the best estimation is obtained by using the average value of a cystatin C-based and a creatinine-based GFR estimating equation.

Shrunken Pore Syndrome: Short introduction

Shrunken Pore Syndrome (SPS) was defined in 2015. The syndrome is characterised by the glomerular filtration of 5-40 kDa molecules being selectively decreased compared to that of molecules <0.2 kDa, e.g. water and creatinine. The mortality is strongly increased in all investigated populations and increases progressively with a decrease in the eGFRcystatin C/eGFRcreatinine ratio used to identify the syndrome. The syndrome might also explain the superiority of eGFRcystatin C over eGFRcreatinine in identifying high-risk kidney patients.

References and literature:

Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ‘Shrunken pore syndrome’

Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting

Glomerular Filtration Rate (GFR)

The Glomerular Filtration Rate (GFR) is the volume of primary urine produced per unit of time, corresponding to the volume of plasma filtered during that same time. GFR can’t be measured in humans, because it is not feasible to measure the filtration flow in the 800,000 human glomeruli. Diagnosis must therefore rely on estimations of GFR. Many potential markers for GFR are available, but only creatinine and cystatin C have been extensively evaluated.

P-Cystatin C and P-Creatinine: recommended as markers of GFR

P-Cystatin C and P-Creatinine are recommended as markers of GFR by both “The international society of nephrology in the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease” and by SBU (Swedish Council on Health Technology Assessment) in their recommendation of 2013 ”Methods to Estimate and Measure Renal Function (GFR)”.


The AACC webinar

The American Association for Clinical Chemistry (AACC) is a global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare.

Register to watch the webinar for free here.

Please sign up through www.aacc.org.



Anders Grubb, MD, PhD
Professor in Clinical Chemistry
Lund University, Sweden

Learn more about cystatin C

Do you want to learn more about cystatin C in general or our cystatin C immunoassay. Our Product Manager for cystatin C is happy to answer all questions you might have. Fill out the form below or send an email to marketing@gentian.com. 


You may also read

#FAQ: Avian antibodies – Immunoglobulin Y(IgY)

Jan 23, 2020

#FAQ: Avian antibodies – Immunoglobulin Y(IgY)

Avian antibodies in our commercial products since 2005 Gentian has applied avian antibodies with great..

CEO Interview at Arctic Securities

Jan 17, 2020

CEO Interview at Arctic Securities

Our CEO Dr. Hilja Ibert recently sat down with Pål Falck in Arctic Securities to have a look at Gentian's..

Diagnostic Efficiency by Gentian - Newsletter H1-2020

Jan 14, 2020

Diagnostic Efficiency by Gentian - Newsletter H1-2020

  Happy New Year 2020 We look forward to exhibiting at and visiting numerous trade shows and congresses..